Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence
Abstract Background This study aims to determine if the intravitreal dexamethasone implant (DEX implant, Ozurdex; Allergan, Inc., Irvine, California) is effective for treating intermediate, posterior, and panuveitis as a monotherapy or adjunctive treatment to systemic immunomodulatory therapies. Met...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SpringerOpen
2020-01-01
|
| シリーズ: | Journal of Ophthalmic Inflammation and Infection |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12348-019-0189-4 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|